Non-Invasive Prenatal Testing (NIPT) Market Outlook - Forecast Trends, Market Size, Share and Growth Analysis Report (2025-2034)
Description
The global non-invasive prenatal testing (NIPT) market was valued at USD 2.27 Billion in 2024, driven by the increasing maternal age and the advancements in genomic sequencing across the globe. The market is expected to grow in the forecast period of 2025-2034 at a CAGR of 14.30% to reach nearly USD 8.64 Billion by 2034.
Non-Invasive Prenatal Testing (NIPT) Market Overview
Non-invasive prenatal testing (NIPT), also known as non-invasive prenatal screening (NIPS), is a method of analyzing the risk of genetic abnormalities in the fetus. It is a safe and highly effective method of screening the conditions for Down syndrome, Edwards syndrome, Patau syndrome, and Turner syndrome, among others. This is generally done by analyzing small fragments of DNA, circulating in pregnant women’s blood by 10 weeks of pregnancy.
The increasing government spending on research and development (R&D) activities on prenatal screening is expected to drive the growth of the non-invasive prenatal testing (NIPT) market. Various laboratories and companies are providing advanced non-invasive prenatal testing (NIFT) to patients, which is propelling the expansion of the market. Moreover, the rising incidences of genetic disorders, the increasing public healthcare expenditure, and growing awareness are estimated to fuel the market growth in the forecast period.
Non-Invasive Prenatal Testing (NIPT) Market Growth Drivers
High Risk of Chromosomal Abnormalities Driving the Market Growth
The high risk of chromosomal abnormalities and the increasing maternal age are propelling the growth of the market. As pregnancy above 35 years has a higher risk of genetic abnormalities, the demand for non-invasive prenatal testing (NIPT) is increasing. Obstetricians are increasingly recommending patients undergo non-invasive tests to ensure healthy delivery of babies, hence positively impacting the market growth.
Non-Invasive Prenatal Testing (NIPT) Market Trends
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
Increased Research Activities to Affect the Market Landscape Significantly
The market is witnessing increased research activities for the development of advanced technologies for NIPT, which is projected to support market growth. With technological advancements, the cost-effectiveness of non-invasive prenatal testing (NIPT) is increasing, which is likely to bolster the market demand in upcoming years.
Rising Investments to Augment Non-Invasive Prenatal Testing (NIPT) Market Size
In June 2024 , California-based BillionToOne, a precision diagnostics company, secured USD 130 million in an oversubscribed, upsized Series D financing round led by prominent investors. The company plans to use the venture capital funding to expand its non-invasive prenatal screening and oncology diagnostics businesses. Such major investments in prenatal screening are set to boost market growth.
Rising Development of Advanced Foetal Tests to Elevate the Non-Invasive Prenatal Testing (NIPT) Market Value
In July 2024 , Italian pharmaceutical company Menarini reported positive results from a clinical study investigating its non-invasive prenatal testing technology on more than 1000 women. The company announced that its non-invasive test can detect foetal abnormalities with higher accuracy and sensitivity in comparison to standard non-invasive prenatal cell-free DNA (cfDNA) screening. The rising development of such screening tests that exhibit higher resolution and accuracy is poised to elevate the market value.
Expansion Beyond High-Risk Pregnancies Likely to Boost Non-Invasive Prenatal Testing (NIPT) Market Demand
Initially, in cases of high-risk pregnancies, non-invasive prenatal testing was recommended for expectant mothers. However, there is a growing shift towards the use of these tests for all pregnant women, irrespective of risk factors. This trend, supported by the growing awareness about the benefits of early and accurate screening, is anticipated to augment market demand.
Non-Invasive Prenatal Testing (NIPT) Market Segmentation
The EMR’s report titled “Non-Invasive Prenatal Testing (NIPT) Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
The Technology Segment Represents Substantial Market Share
Based on the technology, the market is segmented into next-generation sequencing (NGS), microarray, polymerase chain reaction (PCR), and rolling circular amplification. Next-generation sequencing is a dominant technology in the market due to its ability to analyze multiple genes and detect chromosomal abnormalities with high accuracy. Microarray technology is cost-effective and quick and allows screening for specific genetic markers associated with chromosomal abnormalities. However, microarray does not offer the same depth of information as NGS technology.
Non-Invasive Prenatal Testing (NIPT) Market Analysis by Region
North America holds a significant share of the market which can be attributed to the high preterm birth rate, the robust healthcare infrastructure, and the rising disposable income. The increasing incidences of chromosomal abnormalities and the rising awareness regarding the benefits of non-invasive prenatal testing (NIPT) are also propelling the growth of the market. Moreover, with the growing focus of the leading companies on expanding their offerings of non-invasive prenatal testing (NIPT), the market value is likely to experience a surge. Additionally, the introduction of new and technologically advanced tests is significantly contributing to the market growth in this region.
Meanwhile, the Asia Pacific region is also expected to grow significantly in the forecast period, owing to the developing healthcare infrastructure in emerging countries such as Japan and India, among others. The increasing public healthcare expenditure and the rising awareness regarding non-invasive prenatal testing (NIPT) are anticipated to invigorate the market growth. Moreover, technological advancements and innovations in non-invasive prenatal testing (NIPT) are estimated to propel the market expansion in the region.
Leading Players in the Non-Invasive Prenatal Testing (NIPT) Market
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Illumina Inc.
Headquartered in San Diego, California, Illumina is one of the leading biotechnology companies known for its array-based solutions for DNA, RNA, and protein analysis. The company provides advanced sequencing systems such as the NextSeq and NovaSeq platforms, which are widely used for non-invasive prenatal testing.
Thermo Fisher Scientific Corporation
This American-headquartered life science and clinical research company is a global supplier of analytical instruments, chemicals, and consumables, among others. Thermo Fisher's Ion Torrent NGS platforms and AmpliSeq technology for targeted DNA sequencing can help in ensuring accurate prenatal screening.
PerkinElmer Inc.
PerkinElmer, a global provider of technology and service solutions, has a prominent presence in the market and is focused on strengthening its capabilities in molecular diagnostics. The company leverages collaborations with hospitals and clinics to expand its market reach.
Agilent Technologies, Inc.
American global company Agilent Technologies provides instruments, software, and services, as well as consumables for laboratories. The company offers microarray-based solutions which can be used for prenatal testing.
Other key players in the market include F. Hoffmann-La Roche AG, BGI Group, Eurofins Scientific SE, Invitae Corporation, Centogene NV, MedGenome Labs Ltd, Myriad Womens Health Inc., and Qiagen NV.
Key Questions Answered in the Global Non-Invasive Prenatal Testing (NIPT) Market Report
Non-Invasive Prenatal Testing (NIPT) Market Overview
Non-invasive prenatal testing (NIPT), also known as non-invasive prenatal screening (NIPS), is a method of analyzing the risk of genetic abnormalities in the fetus. It is a safe and highly effective method of screening the conditions for Down syndrome, Edwards syndrome, Patau syndrome, and Turner syndrome, among others. This is generally done by analyzing small fragments of DNA, circulating in pregnant women’s blood by 10 weeks of pregnancy.
The increasing government spending on research and development (R&D) activities on prenatal screening is expected to drive the growth of the non-invasive prenatal testing (NIPT) market. Various laboratories and companies are providing advanced non-invasive prenatal testing (NIFT) to patients, which is propelling the expansion of the market. Moreover, the rising incidences of genetic disorders, the increasing public healthcare expenditure, and growing awareness are estimated to fuel the market growth in the forecast period.
Non-Invasive Prenatal Testing (NIPT) Market Growth Drivers
High Risk of Chromosomal Abnormalities Driving the Market Growth
The high risk of chromosomal abnormalities and the increasing maternal age are propelling the growth of the market. As pregnancy above 35 years has a higher risk of genetic abnormalities, the demand for non-invasive prenatal testing (NIPT) is increasing. Obstetricians are increasingly recommending patients undergo non-invasive tests to ensure healthy delivery of babies, hence positively impacting the market growth.
Non-Invasive Prenatal Testing (NIPT) Market Trends
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
Increased Research Activities to Affect the Market Landscape Significantly
The market is witnessing increased research activities for the development of advanced technologies for NIPT, which is projected to support market growth. With technological advancements, the cost-effectiveness of non-invasive prenatal testing (NIPT) is increasing, which is likely to bolster the market demand in upcoming years.
Rising Investments to Augment Non-Invasive Prenatal Testing (NIPT) Market Size
In June 2024 , California-based BillionToOne, a precision diagnostics company, secured USD 130 million in an oversubscribed, upsized Series D financing round led by prominent investors. The company plans to use the venture capital funding to expand its non-invasive prenatal screening and oncology diagnostics businesses. Such major investments in prenatal screening are set to boost market growth.
Rising Development of Advanced Foetal Tests to Elevate the Non-Invasive Prenatal Testing (NIPT) Market Value
In July 2024 , Italian pharmaceutical company Menarini reported positive results from a clinical study investigating its non-invasive prenatal testing technology on more than 1000 women. The company announced that its non-invasive test can detect foetal abnormalities with higher accuracy and sensitivity in comparison to standard non-invasive prenatal cell-free DNA (cfDNA) screening. The rising development of such screening tests that exhibit higher resolution and accuracy is poised to elevate the market value.
Expansion Beyond High-Risk Pregnancies Likely to Boost Non-Invasive Prenatal Testing (NIPT) Market Demand
Initially, in cases of high-risk pregnancies, non-invasive prenatal testing was recommended for expectant mothers. However, there is a growing shift towards the use of these tests for all pregnant women, irrespective of risk factors. This trend, supported by the growing awareness about the benefits of early and accurate screening, is anticipated to augment market demand.
Non-Invasive Prenatal Testing (NIPT) Market Segmentation
The EMR’s report titled “Non-Invasive Prenatal Testing (NIPT) Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
- Instruments
- Consumables
- Reagents
- Next Generation Sequencing (NGS)
- Microarray
- Polymerase Chain Reaction (PCR)
- Rolling Circular Amplification
- Down Syndrome
- Edwards Syndrome
- Patau Syndrome
- Turner Syndrome
- Others
- Hospitals
- Diagnostic Labs
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
The Technology Segment Represents Substantial Market Share
Based on the technology, the market is segmented into next-generation sequencing (NGS), microarray, polymerase chain reaction (PCR), and rolling circular amplification. Next-generation sequencing is a dominant technology in the market due to its ability to analyze multiple genes and detect chromosomal abnormalities with high accuracy. Microarray technology is cost-effective and quick and allows screening for specific genetic markers associated with chromosomal abnormalities. However, microarray does not offer the same depth of information as NGS technology.
Non-Invasive Prenatal Testing (NIPT) Market Analysis by Region
North America holds a significant share of the market which can be attributed to the high preterm birth rate, the robust healthcare infrastructure, and the rising disposable income. The increasing incidences of chromosomal abnormalities and the rising awareness regarding the benefits of non-invasive prenatal testing (NIPT) are also propelling the growth of the market. Moreover, with the growing focus of the leading companies on expanding their offerings of non-invasive prenatal testing (NIPT), the market value is likely to experience a surge. Additionally, the introduction of new and technologically advanced tests is significantly contributing to the market growth in this region.
Meanwhile, the Asia Pacific region is also expected to grow significantly in the forecast period, owing to the developing healthcare infrastructure in emerging countries such as Japan and India, among others. The increasing public healthcare expenditure and the rising awareness regarding non-invasive prenatal testing (NIPT) are anticipated to invigorate the market growth. Moreover, technological advancements and innovations in non-invasive prenatal testing (NIPT) are estimated to propel the market expansion in the region.
Leading Players in the Non-Invasive Prenatal Testing (NIPT) Market
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Illumina Inc.
Headquartered in San Diego, California, Illumina is one of the leading biotechnology companies known for its array-based solutions for DNA, RNA, and protein analysis. The company provides advanced sequencing systems such as the NextSeq and NovaSeq platforms, which are widely used for non-invasive prenatal testing.
Thermo Fisher Scientific Corporation
This American-headquartered life science and clinical research company is a global supplier of analytical instruments, chemicals, and consumables, among others. Thermo Fisher's Ion Torrent NGS platforms and AmpliSeq technology for targeted DNA sequencing can help in ensuring accurate prenatal screening.
PerkinElmer Inc.
PerkinElmer, a global provider of technology and service solutions, has a prominent presence in the market and is focused on strengthening its capabilities in molecular diagnostics. The company leverages collaborations with hospitals and clinics to expand its market reach.
Agilent Technologies, Inc.
American global company Agilent Technologies provides instruments, software, and services, as well as consumables for laboratories. The company offers microarray-based solutions which can be used for prenatal testing.
Other key players in the market include F. Hoffmann-La Roche AG, BGI Group, Eurofins Scientific SE, Invitae Corporation, Centogene NV, MedGenome Labs Ltd, Myriad Womens Health Inc., and Qiagen NV.
Key Questions Answered in the Global Non-Invasive Prenatal Testing (NIPT) Market Report
- What was the global non-invasive prenatal testing (NIPT) market value in 2024?
- What is the global non-invasive prenatal testing (NIPT) market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on product?
- What is the market breakup based on technology?
- What is the market breakup by application?
- Who are the major end users in the market?
- What are the major factors aiding the global non-invasive prenatal testing (NIPT) market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How does the increasing maternal age affect the market landscape?
- What are the major global non-invasive prenatal testing (NIPT) market trends?
- How do the advances in genomics impact the market size?
- Which product will dominate the market share?
- Which technology is expected to have a high market value in the coming years?
- Which application will experience the highest demand in the market segment?
- Which end user is projected to contribute to the highest market growth?
- Who are the key players involved in the non-invasive prenatal testing (NIPT) market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Non-Invasive Prenatal Testing (NIPT) Market Overview
- 3.1 Global Non-Invasive Prenatal Testing (NIPT) Market Historical Value (2018-2024)
- 3.2 Global Non-Invasive Prenatal Testing (NIPT) Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global Non-Invasive Prenatal Testing (NIPT) Market Landscape*
- 5.1 Global Non-Invasive Prenatal Testing (NIPT) Market: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global Non-Invasive Prenatal Testing (NIPT) Market: Product Landscape
- 5.2.1 Analysis by Product
- 5.2.2 Analysis by Technology
- 5.2.3 Analysis by Application
- 6 Global Non-Invasive Prenatal Testing (NIPT) Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 6.2.1 Strengths
- 6.2.2 Weaknesses
- 6.2.3 Opportunities
- 6.2.4 Threats
- 6.3 PESTEL Analysis
- 6.3.1 Political
- 6.3.2 Economic
- 6.3.3 Social
- 6.3.4 Technological
- 6.3.5 Legal
- 6.3.6 Environment
- 6.4 Porter’s Five Forces Model
- 6.4.1 Bargaining Power of Suppliers
- 6.4.2 Bargaining Power of Buyers
- 6.4.3 Threat of New Entrants
- 6.4.4 Threat of Substitutes
- 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global Non-Invasive Prenatal Testing (NIPT) Market Segmentation (218-2034)
- 7.1 Global Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by Product Type
- 7.1.1 Market Overview
- 7.1.2 Instruments
- 7.1.3 Consumables
- 7.1.4 Reagents
- 7.2 Global Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by Technology
- 7.2.1 Market Overview
- 7.2.2 Next Generation Sequencing (NGS)
- 7.2.3 Microarray
- 7.2.4 Polymerase Chain Reaction (PCR)
- 7.2.5 Rolling Circular Amplification
- 7.3 Global Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by Application
- 7.3.1 Market Overview
- 7.3.2 Down Syndrome
- 7.3.3 Edwards Syndrome
- 7.3.4 Patau Syndrome
- 7.3.5 Turner Syndrome
- 7.3.6 Others
- 7.4 Global Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by End User
- 7.4.1 Market Overview
- 7.4.2 Hospitals
- 7.4.3 Diagnostic Labs
- 7.4.4 Others
- 7.5 Global Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by Region
- 7.5.1 Market Overview
- 7.5.2 North America
- 7.5.3 Europe
- 7.5.4 Asia Pacific
- 7.5.5 Latin America
- 7.5.6 Middle East and Africa
- 8 North America Non-Invasive Prenatal Testing (NIPT) Market (218-2034)
- 8.1 North America Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by Product Type
- 8.1.1 Market Overview
- 8.1.2 Instruments
- 8.1.3 Consumables
- 8.1.4 Reagents
- 8.2 North America Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by Technology
- 8.2.1 Market Overview
- 8.2.2 Next Generation Sequencing (NGS)
- 8.2.3 Microarray
- 8.2.4 Polymerase Chain Reaction (PCR)
- 8.2.5 Rolling Circular Amplification
- 8.3 North America Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by Application
- 8.3.1 Market Overview
- 8.3.2 Down Syndrome
- 8.3.3 Edwards Syndrome
- 8.3.4 Patau Syndrome
- 8.3.5 Turner Syndrome
- 8.3.6 Others
- 8.4 North America Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by End User
- 8.4.1 Market Overview
- 8.4.2 Hospitals
- 8.4.3 Diagnostic Labs
- 8.4.4 Others
- 8.5 North America Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by Country
- 8.5.1 United States of America
- 8.5.2 Canada
- 9 Europe Non-Invasive Prenatal Testing (NIPT) Market (218-2034)
- 9.1 Europe Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by Product Type
- 9.1.1 Market Overview
- 9.1.2 Instruments
- 9.1.3 Consumables
- 9.1.4 Reagents
- 9.2 Europe Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by Technology
- 9.2.1 Market Overview
- 9.2.2 Next Generation Sequencing (NGS)
- 9.2.3 Microarray
- 9.2.4 Polymerase Chain Reaction (PCR)
- 9.2.5 Rolling Circular Amplification
- 9.3 Europe Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by Application
- 9.3.1 Market Overview
- 9.3.2 Down Syndrome
- 9.3.3 Edwards Syndrome
- 9.3.4 Patau Syndrome
- 9.3.5 Turner Syndrome
- 9.3.6 Others
- 9.4 Europe Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by End User
- 9.4.1 Market Overview
- 9.4.2 Hospitals
- 9.4.3 Diagnostic Labs
- 9.4.4 Others
- 9.5 Europe Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by Country
- 9.5.1 United Kingdom
- 9.5.2 Germany
- 9.5.3 France
- 9.5.4 Italy
- 9.5.5 Others
- 10 Asia Pacific Non-Invasive Prenatal Testing (NIPT) Market (218-2034)
- 10.1 Asia Pacific Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by Product Type
- 10.1.1 Market Overview
- 10.1.2 Instruments
- 10.1.3 Consumables
- 10.1.4 Reagents
- 10.2 Asia Pacific Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by Technology
- 10.2.1 Market Overview
- 10.2.2 Next Generation Sequencing (NGS)
- 10.2.3 Microarray
- 10.2.4 Polymerase Chain Reaction (PCR)
- 10.2.5 Rolling Circular Amplification
- 10.3 Asia Pacific Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by Application
- 10.3.1 Market Overview
- 10.3.2 Down Syndrome
- 10.3.3 Edwards Syndrome
- 10.3.4 Patau Syndrome
- 10.3.5 Turner Syndrome
- 10.3.6 Others
- 10.4 Asia Pacific Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by End User
- 10.4.1 Market Overview
- 10.4.2 Hospitals
- 10.4.3 Diagnostic Labs
- 10.4.4 Others
- 10.5 Asia Pacific Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by Country
- 10.5.1 China
- 10.5.2 Japan
- 10.5.3 India
- 10.5.4 ASEAN
- 10.5.5 Australia
- 10.5.6 Others
- 11 Latin America Non-Invasive Prenatal Testing (NIPT) Market (218-2034)
- 11.1 Latin America Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by Product Type
- 11.1.1 Market Overview
- 11.1.2 Instruments
- 11.1.3 Consumables
- 11.1.4 Reagents
- 11.2 Latin America Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by Technology
- 11.2.1 Market Overview
- 11.2.2 Next Generation Sequencing (NGS)
- 11.2.3 Microarray
- 11.2.4 Polymerase Chain Reaction (PCR)
- 11.2.5 Rolling Circular Amplification
- 11.3 Latin America Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by Application
- 11.3.1 Market Overview
- 11.3.2 Down Syndrome
- 11.3.3 Edwards Syndrome
- 11.3.4 Patau Syndrome
- 11.3.5 Turner Syndrome
- 11.3.6 Others
- 11.4 Latin America Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by End User
- 11.4.1 Market Overview
- 11.4.2 Hospitals
- 11.4.3 Diagnostic Labs
- 11.4.4 Others
- 11.5 Latin America Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by Country
- 11.5.1 Brazil
- 11.5.2 Argentina
- 11.5.3 Mexico
- 11.5.4 Others
- 12 Middle East and Africa Non-Invasive Prenatal Testing (NIPT) Market (218-2034)
- 12.1 Middle East and Africa Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by Product Type
- 12.1.1 Market Overview
- 12.1.2 Instruments
- 12.1.3 Consumables
- 12.1.4 Reagents
- 12.2 Middle East and Africa Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by Technology
- 12.2.1 Market Overview
- 12.2.2 Next Generation Sequencing (NGS)
- 12.2.3 Microarray
- 12.2.4 Polymerase Chain Reaction (PCR)
- 12.2.5 Rolling Circular Amplification
- 12.3 Middle East and Africa Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by Application
- 12.3.1 Market Overview
- 12.3.2 Down Syndrome
- 12.3.3 Edwards Syndrome
- 12.3.4 Patau Syndrome
- 12.3.5 Turner Syndrome
- 12.3.6 Others
- 12.4 Middle East and Africa Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by End User
- 12.4.1 Market Overview
- 12.4.2 Hospitals
- 12.4.3 Diagnostic Labs
- 12.4.4 Others
- 12.5 Middle East and Africa Non-Invasive Prenatal Testing (NIPT) Market (2018-2034) by Country
- 12.5.1 Saudi Arabia
- 12.5.2 United Arab Emirates
- 12.5.3 Nigeria
- 12.5.4 South Africa
- 12.5.5 Others
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication Year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 13.7 Analysis by Key Players
- 14 Funding and Investment Analysis
- 14.1 Analysis by Funding Instances
- 14.2 Analysis by Type of Funding
- 14.3 Analysis by Funding Amount
- 14.4 Analysis by Leading Players
- 14.5 Analysis by Leading Investors
- 14.6 Analysis by Geography
- 15 Strategic Initiatives
- 15.1 Analysis by Partnership Instances
- 15.2 Analysis by Type of Partnership
- 15.3 Analysis by Leading Players
- 15.4 Analysis by Geography
- 16 Supplier Landscape
- 16.1 Market Share Analysis, By Region (Top 5 Companies)
- 16.1.1 Market Share Analysis: Global
- 16.1.2 Market Share Analysis: North America
- 16.1.3 Market Share Analysis: Europe
- 16.1.4 Market Share Analysis: Asia Pacific
- 16.1.5 Market Share Analysis: Others
- 16.2 Illumina Inc .
- 16.2.1 Financial Analysis
- 16.2.2 Product Portfolio
- 16.2.3 Demographic Reach and Achievements
- 16.2.4 Company News and Development
- 16.2.5 Certifications
- 16.3 Thermo Fisher Scientific Corporation
- 16.3.1 Financial Analysis
- 16.3.2 Product Portfolio
- 16.3.3 Demographic Reach and Achievements
- 16.3.4 Company News and Development
- 16.3.5 Certifications
- 16.4 PerkinElmer Inc .
- 16.4.1 Financial Analysis
- 16.4.2 Product Portfolio
- 16.4.3 Demographic Reach and Achievements
- 16.4.4 Company News and Development
- 16.4.5 Certifications
- 16.5 Agilent Technologies, Inc
- 16.5.1 Financial Analysis
- 16.5.2 Product Portfolio
- 16.5.3 Demographic Reach and Achievements
- 16.5.4 Company News and Development
- 16.5.5 Certifications
- 16.6 F. Hoffmann-La Roche AG
- 16.6.1 Financial Analysis
- 16.6.2 Product Portfolio
- 16.6.3 Demographic Reach and Achievements
- 16.6.4 Company News and Development
- 16.6.5 Certifications
- 16.7 BGI Group
- 16.7.1 Financial Analysis
- 16.7.2 Product Portfolio
- 16.7.3 Demographic Reach and Achievements
- 16.7.4 Company News and Development
- 16.7.5 Certifications
- 16.8 Eurofins Scientific SE
- 16.8.1 Financial Analysis
- 16.8.2 Product Portfolio
- 16.8.3 Demographic Reach and Achievements
- 16.8.4 Company News and Development
- 16.8.5 Certifications
- 16.9 Invitae Corporation
- 16.9.1 Financial Analysis
- 16.9.2 Product Portfolio
- 16.9.3 Demographic Reach and Achievements
- 16.9.4 Company News and Development
- 16.9.5 Certifications
- 16.10 Centogene NV
- 16.10.1 Financial Analysis
- 16.10.2 Product Portfolio
- 16.10.3 Demographic Reach and Achievements
- 16.10.4 Company News and Development
- 16.10.5 Certifications
- 16.11 MedGenome Labs Ltd
- 16.11.1 Financial Analysis
- 16.11.2 Product Portfolio
- 16.11.3 Demographic Reach and Achievements
- 16.11.4 Company News and Development
- 16.11.5 Certifications
- 16.12 Myriad Womens Health Inc .
- 16.12.1 Financial Analysis
- 16.12.2 Product Portfolio
- 16.12.3 Demographic Reach and Achievements
- 16.12.4 Company News and Developments
- 16.12.5 Certifications
- 16.13 Qiagen NV
- 16.13.1 Financial Analysis
- 16.13.2 Product Portfolio
- 16.13.3 Demographic Reach and Achievements
- 16.13.4 Company News and Development
- 16.13.5 Certifications
- 17 Global Non-Invasive Prenatal Testing (NIPT) Market – Distribution Model (Additional Insight)
- 17.1 Overview
- 17.2 Potential Distributors
- 17.3 Key Parameters for Distribution Partner Assessment
- 18 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
